Press release
Peptide Based Metabolic Disorders Therapeutics Market 2024-2033 : Market Size, Top Segments, Leading Region Forecast | Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc
Peptide Based Metabolic Disorders Therapeutics Global Market Report 2024
As per the report, the peptide based metabolic disorders therapeutics market size has grown rapidly in recent years. It will grow from $26.03 billion in 2023 to $29.89 billion in 2024 at a compound annual growth rate (CAGR) of 14.8%. The peptide based metabolic disorders therapeutics market size is expected to see rapid growth in the next few years. It will grow to $52.16 billion in 2028 at a compound annual growth rate (CAGR) of 14.9%.
Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp
Obesity Rise Driving Growth In Peptide-Based Metabolic Disorders Therapeutics
The rising prevalence of obesity is expected to propel the growth of the peptide-based metabolic disorders therapeutic market going forward. Obesity is a medical condition characterized by excessive body fat accumulation that poses a health risk. The increasing cases of obesity are due to sedentary lifestyles, unhealthy dietary habits, genetic predisposition, and environmental influences promoting calorie-rich diets and physical inactivity. Peptide-based metabolic disorders therapeutics aim to manage conditions such as obesity by leveraging peptides to regulate metabolic functions, improve insulin sensitivity, and control appetite, thereby enhancing patient health outcomes and reducing long-term health risks associated with these chronic disorders. For instance, in May 2023, according to a report published by the Office for Health Improvement and Disparities, a UK-based governmental body, it was noted that in the period from 2021 to 2022, 63.8% of adults aged 18 years and older in England were estimated to be overweight or living with obesity, marking a slight increase from 63.3% in the previous year. Therefore, the rising prevalence of obesity is driving the peptide-based metabolic disorder therapeutics market.
Innovative Developments In Peptide-Based Therapeutics Biosimilars
Major peptide-based metabolic disorders therapeutics market companies are developing innovative peptide-based treatments, such as anti-diabetic biosimilars, to address unmet medical needs and expand patient treatment options. Peptide-based anti-diabetic biosimilars refer to therapeutic drugs that mimic existing peptide-based therapies for diabetes, offering comparable efficacy and safety profiles to established medications while potentially lowering treatment costs through competitive pricing strategies. For instance, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Lirafit, a biosimilar version of the popular anti-diabetic drug Liraglutide in India. It belongs to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This class of drugs mimics the action of the naturally occurring GLP-1 hormone, which is crucial in regulating blood sugar levels. This biosimilar has undergone clinical trials demonstrating its effectiveness in lowering glycemic parameters, promoting weight reduction, and enhancing cardiovascular safety. These are crucial benefits for managing diabetes and associated conditions such as obesity and cardiovascular diseases.
The peptide based metabolic disorders therapeutics market covered in this report is segmented -
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16764&type=discount
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group
Contents of the report:
1. Executive Summary
2. Peptide Based Metabolic Disorders Therapeutics Market Report Structure
3. Peptide Based Metabolic Disorders Therapeutics Market Trends And Strategies
4. Peptide Based Metabolic Disorders Therapeutics Market - Macro Economic Scenario
5. Peptide Based Metabolic Disorders Therapeutics Market Size And Growth
…..
27. Peptide Based Metabolic Disorders Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peptide Based Metabolic Disorders Therapeutics Market 2024-2033 : Market Size, Top Segments, Leading Region Forecast | Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc here
News-ID: 3630700 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Peptide
ShiLai Peptide to Invest $32 Million in State-of-the-Art Peptide Laboratory in H …
ShiLai Peptide's CEO, Luo Binhua, said the investment reflects the company's commitment to a "new science model" that integrates research-driven development, controlled production, and specialized customer support.
ShiLai Peptide [https://retatrutidesupplier.com/], a leading provider of high-purity, customizable research peptides, announced plans to invest $32 million to build a state-of-the-art peptide research and production laboratory in Hangzhou. The facility is designed to meet world-class GMP standards, aiming to strengthen ShiLai's global supply of…
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth…
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global…
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
